gland pharma glp-1 capacity manufacturing Drug Manufacturing: Expansion & Tech Transfer The GLP-1 boom: Challenges, trends, – Gland Pharma Projects Growth Through

Proven to deliver safe and sustainable weight loss with long-term results

Ongoing Support : From regular check-ins to nutrition and fitness advice, were with you every step of the way

Second Natures medicated weight-loss programme combines Wegovy with support from registered dietitians and a structured habit-change programme

A phase 2 trial of semaglutide 2.4 mg in 71 cirrhotic patients confirmed an acceptable safety profile without significant decompensation events, although the primary histological endpoint was not met, possibly due to the limited ability of antifibrotic remodeling to achieve biopsy-detectable fibrosis stage improvement in established cirrhosis over 48 weeks [46]